{
  "pmcid": "PMC10880264",
  "pmid": "38377518",
  "title": "Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study",
  "overall_score": 0.47229015643353145,
  "num_benchmarks": 4,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.2373613255065784,
      "total_samples": 3,
      "ground_truth_annotations": {
        "count": 3,
        "matched_count": 1,
        "unmatched_count": 2,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.7120839765197352,
            "annotation": {
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "PMID": 38377518,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-adjusted trough concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "Drug(s)": "escitalopram"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "PMID": {
                "ground_truth": 38377518,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK",
                "score": 1.0,
                "match_status": "match"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": "",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Specialty Population": {
                "ground_truth": "Pediatric",
                "prediction": "Pediatric",
                "score": 1.0,
                "match_status": "match"
              },
              "Metabolizer types": {
                "ground_truth": "intermediate metabolizer",
                "prediction": "intermediate metabolizer",
                "score": 1.0,
                "match_status": "match"
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "PD/PK terms": {
                "ground_truth": "dose-adjusted trough concentrations of",
                "prediction": "AUC0-24",
                "score": 0.8892078995704651,
                "match_status": "partial_match"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": "",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Population types": {
                "ground_truth": "in children with",
                "prediction": "in youth with a first-degree relative with bipolar I disorder",
                "score": 0.880400538444519,
                "match_status": "partial_match"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Depression, Other:Anxiety Disorders",
                "prediction": "Disease:bipolar disorder",
                "score": 0.8780490159988403,
                "match_status": "partial_match"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "or",
                "prediction": "",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Metabolizer types": {
                "ground_truth": "normal metabolizer",
                "prediction": "",
                "score": 0.881938099861145,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452390346,
              "Variant/Haplotypes": "intermediate",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).\" \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-adjusted trough concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "1452390346",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452390346,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).\" \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-adjusted trough concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "1452390346",
              "_expanded_from_multi_variant": true
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 15,
        "items": [
          {
            "variant": "IM",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "IM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "NM",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "NM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "RM",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "RM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "UM",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "UM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizers had increased TEASAP akathisia scores.",
              "Sentence": "CYP2D6 IM is associated with increased akathisia in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores.",
                "Individuals with slower CYP2D6 phenotypes may be at increased risk of experiencing akathisia or worsening impulsivity.",
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50)."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "IM",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "IM",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizers had increased TEASAP akathisia scores.",
              "Sentence": "CYP2D6 IM is associated with increased akathisia in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores.",
                "Individuals with slower CYP2D6 phenotypes may be at increased risk of experiencing akathisia or worsening impulsivity.",
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50)."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizers had increased TEASAP akathisia scores.",
              "Sentence": "CYP2D6 IM is associated with increased akathisia in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores.",
                "Individuals with slower CYP2D6 phenotypes may be at increased risk of experiencing akathisia or worsening impulsivity.",
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50)."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "NM",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "NM",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizers had increased TEASAP akathisia scores.",
              "Sentence": "CYP2D6 IM is associated with increased akathisia in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores.",
                "Individuals with slower CYP2D6 phenotypes may be at increased risk of experiencing akathisia or worsening impulsivity.",
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50)."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HTR2A",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "HTR2A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores.",
              "Sentence": "Genotype HTR2A A/A is associated with increased self-injury, suicidality, and harm to others in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "A/A, A/G",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Other:self-injury",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "subscale scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP 'Self-injury, Suicidality, and Harm to Others' subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017).",
                "Emergence of adverse events was determined by study clinicians, and symptoms were tracked using the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) and Pediatric Adverse Events Rating Scale."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "A/A",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "A/A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores.",
              "Sentence": "Genotype HTR2A A/A is associated with increased self-injury, suicidality, and harm to others in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "A/A, A/G",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Other:self-injury",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "subscale scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP 'Self-injury, Suicidality, and Harm to Others' subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017).",
                "Emergence of adverse events was determined by study clinicians, and symptoms were tracked using the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) and Pediatric Adverse Events Rating Scale."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HTR2A",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "HTR2A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores.",
              "Sentence": "Genotype HTR2A A/A is associated with increased self-injury, suicidality, and harm to others in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "A/A, A/G",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Other:self-injury",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "subscale scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP 'Self-injury, Suicidality, and Harm to Others' subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017).",
                "Emergence of adverse events was determined by study clinicians, and symptoms were tracked using the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) and Pediatric Adverse Events Rating Scale."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "A/G",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant/Haplotypes": "A/G",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores.",
              "Sentence": "Genotype HTR2A A/A is associated with increased self-injury, suicidality, and harm to others in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "A/A, A/G",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Other:self-injury",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "subscale scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP 'Self-injury, Suicidality, and Harm to Others' subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017).",
                "Emergence of adverse events was determined by study clinicians, and symptoms were tracked using the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) and Pediatric Adverse Events Rating Scale."
              ],
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.8342850736918903,
      "total_samples": 7,
      "ground_truth_annotations": {
        "count": 7,
        "matched_count": 7,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8614450752735138,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "HTR2A",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "HTR2A",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "A/G, A/A",
                "score": 0.85505211353302,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "self-injury, suicidality",
                "score": 0.9304036498069763,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "HTR2A G/G",
                "score": 0.8289949893951416,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8385718524456024,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "CYP2D6",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2D6",
                "score": 0.8632352352142334,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "IM, PM",
                "score": 0.8439474701881409,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "akathisia",
                "score": 0.8501980304718018,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2D6 NM",
                "score": 0.8283377885818481,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8385718524456024,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "IM",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2D6",
                "score": 0.8632352352142334,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "IM, PM",
                "score": 0.8439474701881409,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "akathisia",
                "score": 0.8501980304718018,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2D6 NM",
                "score": 0.8283377885818481,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8385718524456024,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "PM",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2D6",
                "score": 0.8632352352142334,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "IM, PM",
                "score": 0.8439474701881409,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "akathisia",
                "score": 0.8501980304718018,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2D6 NM",
                "score": 0.8283377885818481,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7416032254695892,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "CYP2C19",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2C19",
                "score": 0.8735596537590027,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "metabolism/PK",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "IM, NM, RM",
                "score": 0.8551374673843384,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "serum escitalopram levels",
                "score": 0.8676972985267639,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2C19 PM",
                "score": 0.8196378350257874,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7416032254695892,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "RM",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2C19",
                "score": 0.8735596537590027,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "metabolism/PK",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "IM, NM, RM",
                "score": 0.8551374673843384,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "serum escitalopram levels",
                "score": 0.8676972985267639,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2C19 PM",
                "score": 0.8196378350257874,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7416032254695892,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "IM",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2C19",
                "score": 0.8735596537590027,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "metabolism/PK",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "IM, NM, RM",
                "score": 0.8551374673843384,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "serum escitalopram levels",
                "score": 0.8676972985267639,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2C19 PM",
                "score": 0.8196378350257874,
                "match_status": "partial_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 3,
        "items": [
          {
            "variant": "NM",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "NM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had significantly higher dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM, NM, RM is associated with increased metabolism of escitalopram in youth with a family history of bipolar disorder.",
              "Alleles": "IM, NM, RM",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "metabolism",
              "Phenotype": "serum escitalopram levels",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "not stated",
              "Population types": "in youth with",
              "Population Phenotypes or diseases": "bipolar disorder",
              "Multiple phenotypes or diseases And/or": "not stated",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 PM",
              "Comparison Metabolizer types": "poor metabolizer",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "We hypothesized that CYP450 enzyme metabolizer phenotypes (CYP2C19, CYP2D6) would predict dose-normalized pharmacokinetic parameters and that slower CYP2C19 metabolizers would confer increased risk of escitalopram-related adverse events.",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "A/G",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "A/G",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP self-injury, suicidality scores.",
              "Sentence": "HTR2A A/G, A/A is associated with increased risk of self-injury, suicidality when treated with escitalopram.",
              "Alleles": "A/G, A/A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "not applicable",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "self-injury, suicidality",
              "Multiple phenotypes And/or": "not stated",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "not stated",
              "Population types": "in youth with",
              "Population Phenotypes or diseases": "bipolar disorder",
              "Multiple phenotypes or diseases And/or": "not stated",
              "Comparison Allele(s) or Genotype(s)": "HTR2A G/G",
              "Comparison Metabolizer types": "not applicable",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP \"Self-injury, Suicidality, and Harm to Others\" subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017)."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "A/A",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "A/A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP self-injury, suicidality scores.",
              "Sentence": "HTR2A A/G, A/A is associated with increased risk of self-injury, suicidality when treated with escitalopram.",
              "Alleles": "A/G, A/A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "not applicable",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "self-injury, suicidality",
              "Multiple phenotypes And/or": "not stated",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "not stated",
              "Population types": "in youth with",
              "Population Phenotypes or diseases": "bipolar disorder",
              "Multiple phenotypes or diseases And/or": "not stated",
              "Comparison Allele(s) or Genotype(s)": "HTR2A G/G",
              "Comparison Metabolizer types": "not applicable",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP \"Self-injury, Suicidality, and Harm to Others\" subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017)."
              ],
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "functional_analysis": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.7539811833699545,
      "total_samples": 4,
      "ground_truth_annotations": {
        "count": 4,
        "matched_count": 4,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.7034544208470512,
            "annotation": {
              "Study Parameters ID": 1452390361,
              "Variant Annotation ID": 1452390352,
              "Study Type": null,
              "Study Cases": 66.0,
              "Study Controls": null,
              "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.017",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452390361,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390352,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 66.0,
                "prediction": 66,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
                "prediction": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram.",
                "score": 0.9587251543998718,
                "match_status": "match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.017",
                "prediction": "= 0.017",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.674042656141169,
            "annotation": {
              "Study Parameters ID": 1452390309,
              "Variant Annotation ID": 1452390301,
              "Study Type": null,
              "Study Cases": 66.0,
              "Study Controls": null,
              "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.09",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452390309,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390301,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 66.0,
                "prediction": 66,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
                "prediction": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram.",
                "score": 0.9587251543998718,
                "match_status": "match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.09",
                "prediction": "= 0.025",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6681274996084325,
            "annotation": {
              "Study Parameters ID": 1452390397,
              "Variant Annotation ID": 1452390389,
              "Study Type": null,
              "Study Cases": 64.0,
              "Study Controls": null,
              "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Akathisia, hyperkinesis and somatic anxiety",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.017",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452390397,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390389,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 64.0,
                "prediction": 66,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Akathisia, hyperkinesis and somatic anxiety",
                "prediction": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram.",
                "score": 0.9581674933433533,
                "match_status": "match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.017",
                "prediction": "= 0.013",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6154854823561275,
            "annotation": {
              "Study Parameters ID": 1452390351,
              "Variant Annotation ID": 1452390346,
              "Study Type": null,
              "Study Cases": 48.0,
              "Study Controls": null,
              "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; dose-normalized AUC0-24",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.025",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=33, Hispanic Caucasian n=6, Black or African n = 6, Multiple or other n=6"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452390351,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390346,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 48.0,
                "prediction": 66,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; dose-normalized AUC0-24",
                "prediction": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram.",
                "score": 0.9632532000541687,
                "match_status": "match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.025",
                "prediction": "= 0.015",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=33, Hispanic Caucasian n=6, Black or African n = 6, Multiple or other n=6",
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 1,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.001",
              "Ratio Stat Type": "HR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}